Supplementary Table S2 from Identifying Mechanisms of Resistance by Circulating Tumor DNA in EVOLVE, a Phase II Trial of Cediranib Plus Olaparib for Ovarian Cancer at Time of PARP Inhibitor Progression
<p>Supplementary Table S2: Sample Summary. List of patients and samples (timepoints) included in the current study.</p>
Wedi'i Gadw mewn:
| Prif Awdur: | |
|---|---|
| Awduron Eraill: | , , , , , , , , , , , , , , , , , , , , |
| Cyhoeddwyd: |
2025
|
| Pynciau: | |
| Tagiau: |
Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!
|
| _version_ | 1849927632785768448 |
|---|---|
| author | Stephanie Lheureux (16797697) |
| author2 | Stephenie D. Prokopec (16797700) Leslie E. Oldfield (16797703) Eduardo Gonzalez-Ochoa (16375918) Jeffrey P. Bruce (16797706) Derek Wong (15135437) Arnavaz Danesh (15135449) Dax Torti (15135467) Jonathan Torchia (16797709) Alexander Fortuna (16797712) Sharanjit Singh (16797715) Matthew Irving (16797718) Kayla Marsh (15135470) Bernard Lam (15051558) Vanessa Speers (16797721) Aleksandra Yosifova (16797724) Ana Oaknin (14956029) Ainhoa Madariaga (15129719) Neesha C. Dhani (16797727) Valerie Bowering (16797730) Amit M. Oza (15129737) Trevor J. Pugh (14940894) |
| author2_role | author author author author author author author author author author author author author author author author author author author author author |
| author_facet | Stephanie Lheureux (16797697) Stephenie D. Prokopec (16797700) Leslie E. Oldfield (16797703) Eduardo Gonzalez-Ochoa (16375918) Jeffrey P. Bruce (16797706) Derek Wong (15135437) Arnavaz Danesh (15135449) Dax Torti (15135467) Jonathan Torchia (16797709) Alexander Fortuna (16797712) Sharanjit Singh (16797715) Matthew Irving (16797718) Kayla Marsh (15135470) Bernard Lam (15051558) Vanessa Speers (16797721) Aleksandra Yosifova (16797724) Ana Oaknin (14956029) Ainhoa Madariaga (15129719) Neesha C. Dhani (16797727) Valerie Bowering (16797730) Amit M. Oza (15129737) Trevor J. Pugh (14940894) |
| author_role | author |
| dc.creator.none.fl_str_mv | Stephanie Lheureux (16797697) Stephenie D. Prokopec (16797700) Leslie E. Oldfield (16797703) Eduardo Gonzalez-Ochoa (16375918) Jeffrey P. Bruce (16797706) Derek Wong (15135437) Arnavaz Danesh (15135449) Dax Torti (15135467) Jonathan Torchia (16797709) Alexander Fortuna (16797712) Sharanjit Singh (16797715) Matthew Irving (16797718) Kayla Marsh (15135470) Bernard Lam (15051558) Vanessa Speers (16797721) Aleksandra Yosifova (16797724) Ana Oaknin (14956029) Ainhoa Madariaga (15129719) Neesha C. Dhani (16797727) Valerie Bowering (16797730) Amit M. Oza (15129737) Trevor J. Pugh (14940894) |
| dc.date.none.fl_str_mv | 2025-11-25T13:21:49Z |
| dc.identifier.none.fl_str_mv | 10.1158/1078-0432.30708436 |
| dc.relation.none.fl_str_mv | https://figshare.com/articles/dataset/Supplementary_Table_S2_from_Identifying_Mechanisms_of_Resistance_by_Circulating_Tumor_DNA_in_EVOLVE_a_Phase_II_Trial_of_Cediranib_Plus_Olaparib_for_Ovarian_Cancer_at_Time_of_PARP_Inhibitor_Progression/30708436 |
| dc.rights.none.fl_str_mv | CC BY info:eu-repo/semantics/openAccess |
| dc.subject.none.fl_str_mv | Cancer Methods and Technology Computational Methods Sequence analysis Gynecological Cancers Ovarian cancer Liquid Biopsy |
| dc.title.none.fl_str_mv | Supplementary Table S2 from Identifying Mechanisms of Resistance by Circulating Tumor DNA in EVOLVE, a Phase II Trial of Cediranib Plus Olaparib for Ovarian Cancer at Time of PARP Inhibitor Progression |
| dc.type.none.fl_str_mv | Dataset info:eu-repo/semantics/publishedVersion dataset |
| description | <p>Supplementary Table S2: Sample Summary. List of patients and samples (timepoints) included in the current study.</p> |
| eu_rights_str_mv | openAccess |
| id | Manara_cd5f611148684058c9c467c16bb504c7 |
| identifier_str_mv | 10.1158/1078-0432.30708436 |
| network_acronym_str | Manara |
| network_name_str | ManaraRepo |
| oai_identifier_str | oai:figshare.com:article/30708436 |
| publishDate | 2025 |
| repository.mail.fl_str_mv | |
| repository.name.fl_str_mv | |
| repository_id_str | |
| rights_invalid_str_mv | CC BY |
| spelling | Supplementary Table S2 from Identifying Mechanisms of Resistance by Circulating Tumor DNA in EVOLVE, a Phase II Trial of Cediranib Plus Olaparib for Ovarian Cancer at Time of PARP Inhibitor ProgressionStephanie Lheureux (16797697)Stephenie D. Prokopec (16797700)Leslie E. Oldfield (16797703)Eduardo Gonzalez-Ochoa (16375918)Jeffrey P. Bruce (16797706)Derek Wong (15135437)Arnavaz Danesh (15135449)Dax Torti (15135467)Jonathan Torchia (16797709)Alexander Fortuna (16797712)Sharanjit Singh (16797715)Matthew Irving (16797718)Kayla Marsh (15135470)Bernard Lam (15051558)Vanessa Speers (16797721)Aleksandra Yosifova (16797724)Ana Oaknin (14956029)Ainhoa Madariaga (15129719)Neesha C. Dhani (16797727)Valerie Bowering (16797730)Amit M. Oza (15129737)Trevor J. Pugh (14940894)CancerMethods and TechnologyComputational MethodsSequence analysisGynecological CancersOvarian cancerLiquid Biopsy<p>Supplementary Table S2: Sample Summary. List of patients and samples (timepoints) included in the current study.</p>2025-11-25T13:21:49ZDatasetinfo:eu-repo/semantics/publishedVersiondataset10.1158/1078-0432.30708436https://figshare.com/articles/dataset/Supplementary_Table_S2_from_Identifying_Mechanisms_of_Resistance_by_Circulating_Tumor_DNA_in_EVOLVE_a_Phase_II_Trial_of_Cediranib_Plus_Olaparib_for_Ovarian_Cancer_at_Time_of_PARP_Inhibitor_Progression/30708436CC BYinfo:eu-repo/semantics/openAccessoai:figshare.com:article/307084362025-11-25T13:21:49Z |
| spellingShingle | Supplementary Table S2 from Identifying Mechanisms of Resistance by Circulating Tumor DNA in EVOLVE, a Phase II Trial of Cediranib Plus Olaparib for Ovarian Cancer at Time of PARP Inhibitor Progression Stephanie Lheureux (16797697) Cancer Methods and Technology Computational Methods Sequence analysis Gynecological Cancers Ovarian cancer Liquid Biopsy |
| status_str | publishedVersion |
| title | Supplementary Table S2 from Identifying Mechanisms of Resistance by Circulating Tumor DNA in EVOLVE, a Phase II Trial of Cediranib Plus Olaparib for Ovarian Cancer at Time of PARP Inhibitor Progression |
| title_full | Supplementary Table S2 from Identifying Mechanisms of Resistance by Circulating Tumor DNA in EVOLVE, a Phase II Trial of Cediranib Plus Olaparib for Ovarian Cancer at Time of PARP Inhibitor Progression |
| title_fullStr | Supplementary Table S2 from Identifying Mechanisms of Resistance by Circulating Tumor DNA in EVOLVE, a Phase II Trial of Cediranib Plus Olaparib for Ovarian Cancer at Time of PARP Inhibitor Progression |
| title_full_unstemmed | Supplementary Table S2 from Identifying Mechanisms of Resistance by Circulating Tumor DNA in EVOLVE, a Phase II Trial of Cediranib Plus Olaparib for Ovarian Cancer at Time of PARP Inhibitor Progression |
| title_short | Supplementary Table S2 from Identifying Mechanisms of Resistance by Circulating Tumor DNA in EVOLVE, a Phase II Trial of Cediranib Plus Olaparib for Ovarian Cancer at Time of PARP Inhibitor Progression |
| title_sort | Supplementary Table S2 from Identifying Mechanisms of Resistance by Circulating Tumor DNA in EVOLVE, a Phase II Trial of Cediranib Plus Olaparib for Ovarian Cancer at Time of PARP Inhibitor Progression |
| topic | Cancer Methods and Technology Computational Methods Sequence analysis Gynecological Cancers Ovarian cancer Liquid Biopsy |